TCM Biotech International Corp. Share Price

Equities

4169

TW0004169008

Pharmaceuticals

End-of-day quote Taipei Exchange 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
55.7 TWD -0.36% Intraday chart for TCM Biotech International Corp. +10.08% -4.30%

Financials

Sales 2024 * 1.08B 33.24M 2.77B Sales 2025 * - Capitalization 3.29B 101M 8.43B
Net income 2024 * 34M 1.04M 87.15M Net income 2025 * - EV / Sales 2024 * 3.12 x
Net Debt 2024 * 86M 2.64M 220M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
77.4 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
0.11%
Yield 2025 *
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.36%
1 week+10.08%
Current month+7.53%
1 month+5.29%
3 months-2.28%
6 months-7.63%
Current year-4.30%
More quotes
1 week
50.30
Extreme 50.3
58.20
1 month
49.75
Extreme 49.75
58.20
Current year
49.75
Extreme 49.75
61.00
1 year
49.29
Extreme 49.2917
71.41
3 years
26.39
Extreme 26.3924
71.41
5 years
18.35
Extreme 18.3485
71.41
10 years
17.37
Extreme 17.3685
71.41
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 26/08/26
Chairman - 23/10/23
Members of the board TitleAgeSince
Director/Board Member - 15/12/15
Chairman - 23/10/23
Director/Board Member - -
More insiders
Date Price Change Volume
26/24/26 55.7 -0.36% 44,159
25/24/25 55.9 -3.79% 54,333
24/24/24 58.1 +7.79% 325,246
23/24/23 53.9 +2.28% 179,312
22/24/22 52.7 +4.15% 140,309

End-of-day quote Taipei Exchange, April 26, 2024

More quotes
TCM BIOTECH INTERNATIONAL CORP. is a Taiwan-based company principally engaged in the detection and development of new medicine for liver disease. The Company's main businesses include the development of new medicine, which are mainly used for the treatment of hepatitis C and non-alcoholic fatty liver and other disease, manufacture and sales of dietary supplements and botanical raw materials, the sales of western medicine products and medical equipment, which are mainly used for the treatment of orthopedic disorders, cardiovascular disorders, oncology disorders and others, sales agent of organic products. The Company distributes its products both in domestic markets and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
55.7 TWD
Average target price
113 TWD
Spread / Average Target
+102.87%
Consensus